Medifast Signs Agreement With The Xerox Corporation To Install The Latest Digital Printing Technology, DocuColor iGen3 Printing Press

OWINGS MILLS, Md., Dec. 14 /PRNewswire-FirstCall/ -- Medifast, Inc. announced today that it has signed an agreement with the Xerox Corporation to purchase a DocuColor iGen3 Digital Production Press for Sunrise Distributing, a division of Medifast, Inc. on the eastern shore in Ridgely, Maryland. This state-of-the-art press will enhance the company's business platform and is estimated to lower marketing printing costs by up to 30%. Physicians, Health Advisors, and clinics will now be able to customize their Medifast and Hi-Energy product and program materials to their customers at significantly lower cost per patient.

The iGen production press is the latest in digital printing technology from Xerox, delivering smart press technology with state-of-the-art productivity, quality and economics to meet customer needs. The equipment allows for printing production in an on-demand capacity with fast turnarounds and personalization of printed material. The iGen equipment delivers up to 6,000 four-color impressions an hour, the fastest sheet-fed digital color press on the market today.

Sunrise Distributing handles all of Medifast's distribution, fulfillment and mailing activities. The Company has upgraded to the iGen printing technology to improve quality and efficiencies in its world-class print shop and mail house, which services the Medifast business, partners and third party clients. The Company has invested in the equipment to enhance its robust technology model to service its customers at a fraction of the cost.

The installation of the iGen Digital Production press will support the Company's robust clinical research effort of its medical meal replacement products and enhance opportunities to partner with corporations and HMOs as well as provide state-of-the-art printing services to support direct customers, physicians, clinics and retail customers.

This release contains forward-looking statements, which may involve known, and unknown risks, uncertainties and other factors that may cause Medifast's actual results and performance in future periods to be materially different from any future results or performance suggested by these statements. Medifast cautions investors not to place undue reliance on forward-looking statements, which speak only to management's expectation on this date.

CONTACT: Jeremy Hunt, Investor Relations Specialist, Medifast, Inc.,+1-410-504-8196; or Ken Sgro, CEOcast, Inc. for Medifast, +1-212-732-4300

Web site: http://www.medifastdiet.com/